157 related articles for article (PubMed ID: 9863267)
21. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan.
Chen CY; Kumar RN; Feng YH; Ho CH; You JY; Liao CC; Tseng CH; Mavros P; Gerth WC; Chen YC
J Antimicrob Chemother; 2006 Jun; 57(6):1181-8. PubMed ID: 16595642
[TBL] [Abstract][Full Text] [Related]
22. Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients.
Wasan KM; Wong JC; Corr T; Pritchard S
Cancer Chemother Pharmacol; 2006 Jan; 57(1):120-4. PubMed ID: 16094544
[TBL] [Abstract][Full Text] [Related]
23. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
24. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
[TBL] [Abstract][Full Text] [Related]
25. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino J; Markham L; Matulionyte R; Rives V; Lew D
Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering.
Rosa G; Dell'Utri D; Conti G; Pelaia P; Cogliati A; Orsi P; Gasparetto A
Arch Intern Med; 1997 Jul; 157(14):1589-92. PubMed ID: 9236561
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
[TBL] [Abstract][Full Text] [Related]
28. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
29. Oral rehydration solution to prevent nephrotoxicity of amphotericin B.
Echevarria J; Seas C; Cruz M; Chávez E; Campos M; Cieza J; Gotuzzo E; Llanos A
Am J Trop Med Hyg; 2006 Dec; 75(6):1108-12. PubMed ID: 17172377
[TBL] [Abstract][Full Text] [Related]
30. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
31. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
Imhof A; Walter RB; Schaffner A
Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms and management of amphotericin B-induced nephrotoxicity.
Miano-Mason TM
Cancer Pract; 1997; 5(3):176-81. PubMed ID: 9171554
[TBL] [Abstract][Full Text] [Related]
33. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
34. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
35. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
Paterson DL; David K; Mrsic M; Cetkovsky P; Weng XH; Sterba J; Krivan G; Boskovic D; Lu M; Zhu LP;
J Antimicrob Chemother; 2008 Dec; 62(6):1392-400. PubMed ID: 18812423
[TBL] [Abstract][Full Text] [Related]
36. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
37. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
[TBL] [Abstract][Full Text] [Related]
38. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex.
Perfect JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S401-8. PubMed ID: 15809926
[TBL] [Abstract][Full Text] [Related]
39. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation.
Singhal S; Ellis RW; Jones SG; Miller SJ; Fisher NC; Hastings JG; Mutimer DJ
Liver Transpl; 2000 Sep; 6(5):588-95. PubMed ID: 10980058
[TBL] [Abstract][Full Text] [Related]
40. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
